Maryam Asgari
Concepts (538)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 99 | 2026 | 847 | 20.300 |
Why?
| | Carcinoma, Squamous Cell | 54 | 2024 | 641 | 12.900 |
Why?
| | Melanoma | 25 | 2026 | 761 | 4.250 |
Why?
| | Keratosis, Actinic | 9 | 2024 | 12 | 3.710 |
Why?
| | Dermatology | 12 | 2020 | 128 | 3.520 |
Why?
| | Psoriasis | 8 | 2023 | 112 | 2.590 |
Why?
| | Dermatologic Agents | 8 | 2019 | 68 | 2.540 |
Why?
| | Genetic Loci | 6 | 2020 | 261 | 2.120 |
Why?
| | Vitamin D | 10 | 2021 | 400 | 2.050 |
Why?
| | Neoplasms, Multiple Primary | 4 | 2019 | 58 | 1.930 |
Why?
| | Dermatitis, Atopic | 6 | 2023 | 321 | 1.880 |
Why?
| | Genetic Predisposition to Disease | 13 | 2022 | 2363 | 1.880 |
Why?
| | Keratinocytes | 13 | 2020 | 248 | 1.860 |
Why?
| | California | 22 | 2018 | 475 | 1.860 |
Why?
| | Risk Assessment | 21 | 2023 | 3671 | 1.620 |
Why?
| | Mohs Surgery | 5 | 2021 | 29 | 1.540 |
Why?
| | Transplant Recipients | 6 | 2021 | 180 | 1.460 |
Why?
| | Incidence | 23 | 2024 | 2879 | 1.350 |
Why?
| | Humans | 163 | 2026 | 144759 | 1.280 |
Why?
| | Risk Factors | 41 | 2026 | 10779 | 1.260 |
Why?
| | Cohort Studies | 30 | 2023 | 5960 | 1.230 |
Why?
| | Organ Transplantation | 7 | 2021 | 247 | 1.230 |
Why?
| | Aged | 63 | 2026 | 25913 | 1.210 |
Why?
| | Middle Aged | 69 | 2026 | 35875 | 1.200 |
Why?
| | Fluorouracil | 5 | 2023 | 235 | 1.150 |
Why?
| | Registries | 9 | 2026 | 2385 | 1.100 |
Why?
| | Polymorphism, Single Nucleotide | 12 | 2024 | 2145 | 1.090 |
Why?
| | Genome-Wide Association Study | 11 | 2024 | 1406 | 1.060 |
Why?
| | Male | 93 | 2026 | 72315 | 1.040 |
Why?
| | Aged, 80 and over | 31 | 2026 | 8265 | 1.030 |
Why?
| | Papillomaviridae | 4 | 2019 | 115 | 0.970 |
Why?
| | Biological Products | 3 | 2021 | 252 | 0.970 |
Why?
| | Female | 91 | 2026 | 78271 | 0.950 |
Why?
| | Needs Assessment | 6 | 2018 | 404 | 0.940 |
Why?
| | Immunosuppressive Agents | 6 | 2021 | 846 | 0.940 |
Why?
| | Health Services Needs and Demand | 3 | 2012 | 280 | 0.910 |
Why?
| | Dietary Supplements | 5 | 2014 | 576 | 0.900 |
Why?
| | Follow-Up Studies | 17 | 2020 | 5408 | 0.890 |
Why?
| | Carcinoma, Merkel Cell | 5 | 2016 | 16 | 0.870 |
Why?
| | Skin Pigmentation | 3 | 2020 | 48 | 0.860 |
Why?
| | Skin Diseases | 3 | 2023 | 149 | 0.830 |
Why?
| | Precision Medicine | 3 | 2022 | 457 | 0.800 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 5 | 2013 | 338 | 0.800 |
Why?
| | Adult | 52 | 2024 | 40449 | 0.790 |
Why?
| | Delivery of Health Care | 4 | 2020 | 947 | 0.770 |
Why?
| | Retrospective Studies | 30 | 2023 | 17066 | 0.740 |
Why?
| | Sunlight | 4 | 2018 | 78 | 0.730 |
Why?
| | Sex Factors | 6 | 2019 | 2112 | 0.730 |
Why?
| | Evidence-Based Medicine | 3 | 2019 | 732 | 0.700 |
Why?
| | Carcinoma | 2 | 2020 | 228 | 0.680 |
Why?
| | Mendelian Randomization Analysis | 1 | 2021 | 55 | 0.670 |
Why?
| | Genetic Background | 1 | 2020 | 16 | 0.660 |
Why?
| | SEER Program | 3 | 2017 | 224 | 0.660 |
Why?
| | Early Detection of Cancer | 3 | 2023 | 463 | 0.660 |
Why?
| | Hidradenitis Suppurativa | 1 | 2020 | 11 | 0.650 |
Why?
| | Calcineurin Inhibitors | 1 | 2020 | 69 | 0.640 |
Why?
| | Valproic Acid | 1 | 2020 | 47 | 0.630 |
Why?
| | Drug Approval | 2 | 2019 | 89 | 0.600 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2020 | 80 | 0.600 |
Why?
| | Orphan Drug Production | 1 | 2019 | 5 | 0.600 |
Why?
| | Women, Working | 1 | 2019 | 12 | 0.600 |
Why?
| | Antihypertensive Agents | 3 | 2018 | 510 | 0.590 |
Why?
| | Point-of-Care Systems | 1 | 2021 | 187 | 0.590 |
Why?
| | Myotonic Dystrophy | 1 | 2019 | 10 | 0.580 |
Why?
| | HLA-DRB1 Chains | 1 | 2019 | 109 | 0.580 |
Why?
| | Managed Care Programs | 3 | 2017 | 138 | 0.580 |
Why?
| | Salaries and Fringe Benefits | 1 | 2019 | 60 | 0.580 |
Why?
| | Proportional Hazards Models | 9 | 2017 | 1325 | 0.580 |
Why?
| | Epidemiologic Methods | 1 | 2019 | 89 | 0.570 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2020 | 220 | 0.560 |
Why?
| | Rare Diseases | 1 | 2019 | 113 | 0.560 |
Why?
| | Patient Care | 1 | 2019 | 118 | 0.560 |
Why?
| | Genes, MHC Class II | 1 | 2018 | 76 | 0.550 |
Why?
| | Photosensitizing Agents | 1 | 2018 | 42 | 0.550 |
Why?
| | Aminoquinolines | 1 | 2017 | 18 | 0.540 |
Why?
| | Vitamin D Deficiency | 3 | 2021 | 186 | 0.540 |
Why?
| | Physicians, Women | 1 | 2019 | 88 | 0.540 |
Why?
| | Sex Distribution | 6 | 2017 | 386 | 0.530 |
Why?
| | Vitamins | 5 | 2021 | 178 | 0.530 |
Why?
| | Databases, Factual | 8 | 2019 | 1486 | 0.530 |
Why?
| | Lentigo | 1 | 2017 | 6 | 0.530 |
Why?
| | Models, Statistical | 2 | 2019 | 681 | 0.530 |
Why?
| | Lithium | 1 | 2017 | 42 | 0.520 |
Why?
| | DNA Virus Infections | 1 | 2017 | 3 | 0.510 |
Why?
| | Haplotypes | 2 | 2018 | 490 | 0.510 |
Why?
| | Electronic Health Records | 3 | 2021 | 1173 | 0.500 |
Why?
| | Young Adult | 19 | 2023 | 14105 | 0.500 |
Why?
| | Lymph Node Excision | 2 | 2015 | 173 | 0.490 |
Why?
| | Interferon Regulatory Factors | 1 | 2016 | 44 | 0.480 |
Why?
| | Glucocorticoids | 1 | 2020 | 535 | 0.480 |
Why?
| | Patient Satisfaction | 2 | 2011 | 704 | 0.470 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 684 | 0.460 |
Why?
| | HLA Antigens | 1 | 2017 | 225 | 0.460 |
Why?
| | Genomics | 2 | 2019 | 834 | 0.460 |
Why?
| | Bacterial Infections | 1 | 2017 | 246 | 0.450 |
Why?
| | Prognosis | 13 | 2018 | 4282 | 0.450 |
Why?
| | Membrane Transport Proteins | 1 | 2016 | 154 | 0.450 |
Why?
| | Opioid-Related Disorders | 2 | 2021 | 600 | 0.450 |
Why?
| | Community Health Services | 1 | 2017 | 233 | 0.450 |
Why?
| | Mass Screening | 3 | 2023 | 1347 | 0.440 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 257 | 0.440 |
Why?
| | Research Design | 3 | 2019 | 1135 | 0.440 |
Why?
| | Antigens, Neoplasm | 1 | 2016 | 271 | 0.430 |
Why?
| | Quality of Health Care | 1 | 2019 | 691 | 0.430 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2014 | 20 | 0.420 |
Why?
| | Neoplasms, Second Primary | 1 | 2015 | 100 | 0.420 |
Why?
| | Biomedical Research | 2 | 2019 | 710 | 0.420 |
Why?
| | Skin | 6 | 2022 | 755 | 0.420 |
Why?
| | Herpes Zoster | 1 | 2018 | 315 | 0.410 |
Why?
| | Quality Improvement | 3 | 2020 | 1289 | 0.410 |
Why?
| | United States | 19 | 2026 | 15966 | 0.410 |
Why?
| | Adenocarcinoma, Papillary | 1 | 2013 | 11 | 0.410 |
Why?
| | Models, Biological | 2 | 2019 | 1821 | 0.400 |
Why?
| | Confidence Intervals | 6 | 2017 | 333 | 0.400 |
Why?
| | Odds Ratio | 7 | 2017 | 1075 | 0.400 |
Why?
| | Sirolimus | 1 | 2015 | 281 | 0.400 |
Why?
| | Arthritis, Psoriatic | 1 | 2013 | 15 | 0.390 |
Why?
| | Prevalence | 10 | 2025 | 2834 | 0.390 |
Why?
| | Population Surveillance | 1 | 2016 | 485 | 0.390 |
Why?
| | Carcinoma, Large Cell | 1 | 2013 | 17 | 0.390 |
Why?
| | Kidney Transplantation | 1 | 2019 | 704 | 0.380 |
Why?
| | Risk | 4 | 2019 | 911 | 0.380 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2013 | 91 | 0.370 |
Why?
| | Analgesics, Opioid | 2 | 2021 | 1143 | 0.370 |
Why?
| | Neuroectodermal Tumor, Melanotic | 1 | 2012 | 1 | 0.370 |
Why?
| | Age Distribution | 4 | 2017 | 403 | 0.360 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2019 | 985 | 0.360 |
Why?
| | Logistic Models | 7 | 2018 | 2117 | 0.360 |
Why?
| | Carotenoids | 1 | 2012 | 48 | 0.360 |
Why?
| | Vitamin A | 1 | 2012 | 59 | 0.360 |
Why?
| | Case-Control Studies | 8 | 2026 | 3604 | 0.360 |
Why?
| | Epidermis | 1 | 2012 | 157 | 0.360 |
Why?
| | Adolescent | 19 | 2023 | 22428 | 0.350 |
Why?
| | Skin Aging | 1 | 2011 | 20 | 0.350 |
Why?
| | Lymph Nodes | 1 | 2014 | 502 | 0.340 |
Why?
| | Mitochondria | 1 | 2018 | 984 | 0.340 |
Why?
| | Hypertension | 3 | 2018 | 1263 | 0.330 |
Why?
| | Tea | 1 | 2011 | 17 | 0.330 |
Why?
| | Surgery, Plastic | 1 | 2011 | 52 | 0.330 |
Why?
| | Massachusetts | 3 | 2021 | 180 | 0.320 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2023 | 1137 | 0.310 |
Why?
| | Neoplasm Staging | 7 | 2023 | 1462 | 0.310 |
Why?
| | Contraceptives, Oral | 1 | 2010 | 37 | 0.310 |
Why?
| | HIV Infections | 2 | 2017 | 3154 | 0.310 |
Why?
| | Global Health | 3 | 2025 | 401 | 0.300 |
Why?
| | Age Factors | 6 | 2018 | 3333 | 0.300 |
Why?
| | United States Food and Drug Administration | 3 | 2019 | 203 | 0.300 |
Why?
| | Pemphigus | 2 | 2024 | 8 | 0.280 |
Why?
| | Vaccines | 2 | 2024 | 389 | 0.280 |
Why?
| | Sunbathing | 2 | 2018 | 16 | 0.270 |
Why?
| | Disease Susceptibility | 2 | 2020 | 348 | 0.270 |
Why?
| | Patient Participation | 1 | 2011 | 431 | 0.270 |
Why?
| | Genetic Association Studies | 2 | 2019 | 372 | 0.270 |
Why?
| | Anticholesteremic Agents | 1 | 2009 | 152 | 0.260 |
Why?
| | Enhancer Elements, Genetic | 2 | 2020 | 192 | 0.260 |
Why?
| | Administration, Topical | 2 | 2017 | 150 | 0.260 |
Why?
| | Education, Medical, Continuing | 3 | 2019 | 132 | 0.260 |
Why?
| | Comorbidity | 4 | 2018 | 1658 | 0.250 |
Why?
| | DNA, Viral | 2 | 2012 | 358 | 0.250 |
Why?
| | Hemangiosarcoma | 1 | 2007 | 23 | 0.250 |
Why?
| | Head Movements | 1 | 2007 | 36 | 0.250 |
Why?
| | Practice Patterns, Physicians' | 4 | 2017 | 1356 | 0.250 |
Why?
| | Polymorphism, Genetic | 3 | 2019 | 612 | 0.250 |
Why?
| | Head and Neck Neoplasms | 2 | 2014 | 558 | 0.250 |
Why?
| | Reference Values | 3 | 2017 | 797 | 0.250 |
Why?
| | Morbidity | 3 | 2016 | 323 | 0.240 |
Why?
| | Skin Diseases, Vesiculobullous | 1 | 2006 | 17 | 0.240 |
Why?
| | Survival Rate | 5 | 2017 | 2089 | 0.230 |
Why?
| | Calcifediol | 2 | 2018 | 31 | 0.230 |
Why?
| | Antioxidants | 1 | 2009 | 549 | 0.230 |
Why?
| | Drug Costs | 2 | 2017 | 116 | 0.230 |
Why?
| | Papillomavirus Infections | 4 | 2019 | 345 | 0.230 |
Why?
| | Neoplasm Invasiveness | 3 | 2017 | 508 | 0.230 |
Why?
| | Testicular Hydrocele | 1 | 2025 | 4 | 0.220 |
Why?
| | Computational Biology | 2 | 2020 | 680 | 0.220 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2022 | 299 | 0.220 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 439 | 0.220 |
Why?
| | Prospective Studies | 8 | 2018 | 7990 | 0.220 |
Why?
| | CD4 Lymphocyte Count | 2 | 2017 | 277 | 0.220 |
Why?
| | Ultraviolet Rays | 4 | 2019 | 388 | 0.220 |
Why?
| | Nose | 1 | 2005 | 68 | 0.220 |
Why?
| | Face | 3 | 2019 | 173 | 0.210 |
Why?
| | Infant, Premature, Diseases | 1 | 2006 | 111 | 0.210 |
Why?
| | Treatment Outcome | 9 | 2023 | 11679 | 0.210 |
Why?
| | Pemphigoid, Bullous | 1 | 2024 | 7 | 0.210 |
Why?
| | Photochemotherapy | 2 | 2021 | 39 | 0.210 |
Why?
| | Fibrosarcoma | 1 | 2004 | 23 | 0.210 |
Why?
| | Surgical Flaps | 1 | 2005 | 142 | 0.200 |
Why?
| | Child, Preschool | 9 | 2025 | 11787 | 0.200 |
Why?
| | Surveys and Questionnaires | 8 | 2018 | 6048 | 0.200 |
Why?
| | Molecular Sequence Annotation | 2 | 2020 | 105 | 0.200 |
Why?
| | Eosinophilia | 1 | 2006 | 221 | 0.200 |
Why?
| | Genotype | 3 | 2018 | 1833 | 0.190 |
Why?
| | Severity of Illness Index | 4 | 2023 | 2925 | 0.190 |
Why?
| | Patient Selection | 3 | 2013 | 719 | 0.190 |
Why?
| | Feeding Behavior | 1 | 2009 | 684 | 0.190 |
Why?
| | Insurance Claim Review | 2 | 2015 | 83 | 0.190 |
Why?
| | Receptors, Calcitriol | 2 | 2012 | 55 | 0.190 |
Why?
| | Heterogeneous-Nuclear Ribonucleoprotein Group C | 1 | 2022 | 3 | 0.190 |
Why?
| | Eczema | 1 | 2023 | 66 | 0.180 |
Why?
| | Disease Progression | 3 | 2020 | 2847 | 0.180 |
Why?
| | Health Maintenance Organizations | 2 | 2014 | 104 | 0.180 |
Why?
| | Immunohistochemistry | 3 | 2019 | 1716 | 0.180 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 154 | 0.180 |
Why?
| | Blood Coagulation Disorders | 1 | 2004 | 189 | 0.180 |
Why?
| | Endorphins | 1 | 2021 | 9 | 0.170 |
Why?
| | Immunocompromised Host | 3 | 2019 | 201 | 0.170 |
Why?
| | Ascorbic Acid | 1 | 2022 | 180 | 0.170 |
Why?
| | Multifactorial Inheritance | 2 | 2019 | 202 | 0.170 |
Why?
| | Forkhead Transcription Factors | 1 | 2022 | 202 | 0.170 |
Why?
| | Child | 12 | 2025 | 22633 | 0.170 |
Why?
| | Electronics | 1 | 2021 | 71 | 0.170 |
Why?
| | Rituximab | 1 | 2022 | 209 | 0.170 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2020 | 28 | 0.170 |
Why?
| | Wnt-5a Protein | 1 | 2020 | 24 | 0.160 |
Why?
| | Rheumatic Diseases | 1 | 2022 | 97 | 0.160 |
Why?
| | Internet | 2 | 2017 | 699 | 0.160 |
Why?
| | Causality | 1 | 2021 | 126 | 0.160 |
Why?
| | Venous Thrombosis | 1 | 2022 | 194 | 0.160 |
Why?
| | Quality of Life | 2 | 2017 | 3185 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2017 | 1217 | 0.160 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2020 | 72 | 0.160 |
Why?
| | Pulmonary Embolism | 1 | 2022 | 244 | 0.160 |
Why?
| | Sensitivity and Specificity | 3 | 2015 | 1985 | 0.160 |
Why?
| | Molecular Targeted Therapy | 2 | 2021 | 432 | 0.160 |
Why?
| | Boston | 1 | 2020 | 92 | 0.150 |
Why?
| | Physicians, Primary Care | 2 | 2013 | 207 | 0.150 |
Why?
| | Autoimmune Diseases | 1 | 2024 | 463 | 0.150 |
Why?
| | Neoplasms | 4 | 2021 | 2875 | 0.150 |
Why?
| | Biomarkers | 2 | 2017 | 4271 | 0.150 |
Why?
| | Data Curation | 1 | 2019 | 21 | 0.150 |
Why?
| | Xeroderma Pigmentosum | 1 | 2019 | 9 | 0.150 |
Why?
| | Histocompatibility Testing | 1 | 2019 | 121 | 0.150 |
Why?
| | Thymidine Phosphorylase | 1 | 1999 | 14 | 0.150 |
Why?
| | Antirheumatic Agents | 1 | 2022 | 304 | 0.150 |
Why?
| | Parents | 2 | 2018 | 1403 | 0.140 |
Why?
| | Symbiosis | 1 | 2019 | 81 | 0.140 |
Why?
| | Torso | 1 | 2019 | 36 | 0.140 |
Why?
| | Gene-Environment Interaction | 1 | 2020 | 180 | 0.140 |
Why?
| | Intention to Treat Analysis | 1 | 2018 | 80 | 0.140 |
Why?
| | Repressor Proteins | 1 | 2022 | 437 | 0.140 |
Why?
| | Health Care Surveys | 2 | 2017 | 539 | 0.140 |
Why?
| | Administration, Cutaneous | 1 | 2018 | 125 | 0.140 |
Why?
| | Quantitative Trait Loci | 1 | 2020 | 374 | 0.140 |
Why?
| | Biopsy | 3 | 2013 | 1075 | 0.140 |
Why?
| | Off-Label Use | 1 | 2018 | 49 | 0.140 |
Why?
| | Algorithms | 4 | 2016 | 1837 | 0.140 |
Why?
| | Survival Analysis | 3 | 2016 | 1382 | 0.140 |
Why?
| | Extremities | 1 | 2019 | 140 | 0.140 |
Why?
| | Policy | 1 | 2019 | 146 | 0.140 |
Why?
| | Receptor, Melanocortin, Type 1 | 1 | 2017 | 7 | 0.140 |
Why?
| | Antibodies, Monoclonal | 2 | 2017 | 1519 | 0.130 |
Why?
| | Predictive Value of Tests | 3 | 2013 | 2115 | 0.130 |
Why?
| | Head | 1 | 2019 | 120 | 0.130 |
Why?
| | Injections, Subcutaneous | 1 | 2018 | 164 | 0.130 |
Why?
| | Documentation | 1 | 2019 | 198 | 0.130 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 170 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 965 | 0.130 |
Why?
| | Random Allocation | 1 | 2018 | 363 | 0.130 |
Why?
| | Splenic Rupture | 1 | 1997 | 5 | 0.130 |
Why?
| | Infectious Mononucleosis | 1 | 1997 | 10 | 0.130 |
Why?
| | Ultraviolet Therapy | 1 | 2017 | 17 | 0.130 |
Why?
| | Evidence-Based Practice | 1 | 2019 | 238 | 0.130 |
Why?
| | Cryosurgery | 2 | 2021 | 47 | 0.130 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 199 | 0.130 |
Why?
| | Merkel cell polyomavirus | 1 | 2016 | 4 | 0.130 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2947 | 0.130 |
Why?
| | Disease-Free Survival | 2 | 2016 | 769 | 0.130 |
Why?
| | Drug Utilization | 1 | 2017 | 166 | 0.120 |
Why?
| | Tumor Virus Infections | 1 | 2016 | 49 | 0.120 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2016 | 24 | 0.120 |
Why?
| | Immunotherapy | 1 | 2021 | 653 | 0.120 |
Why?
| | Genotyping Techniques | 1 | 2016 | 69 | 0.120 |
Why?
| | Paraneoplastic Syndromes | 1 | 2016 | 12 | 0.120 |
Why?
| | Family | 2 | 2011 | 679 | 0.120 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2017 | 99 | 0.120 |
Why?
| | Immunity | 1 | 2017 | 139 | 0.120 |
Why?
| | Drug Prescriptions | 1 | 2018 | 284 | 0.120 |
Why?
| | Sunburn | 2 | 2018 | 26 | 0.120 |
Why?
| | Infant, Newborn | 4 | 2025 | 6429 | 0.120 |
Why?
| | Infant | 5 | 2025 | 10034 | 0.120 |
Why?
| | International Classification of Diseases | 2 | 2015 | 147 | 0.120 |
Why?
| | Aspergillus | 1 | 2015 | 18 | 0.120 |
Why?
| | Spondylitis, Ankylosing | 1 | 2016 | 43 | 0.120 |
Why?
| | Genetic Variation | 1 | 2021 | 983 | 0.120 |
Why?
| | Gene Frequency | 1 | 2017 | 481 | 0.120 |
Why?
| | Spondylarthritis | 1 | 2016 | 50 | 0.120 |
Why?
| | Pharmaceutical Services | 1 | 2016 | 78 | 0.120 |
Why?
| | Aspergillosis | 1 | 2015 | 23 | 0.110 |
Why?
| | Voriconazole | 1 | 2015 | 21 | 0.110 |
Why?
| | Linear Models | 1 | 2018 | 854 | 0.110 |
Why?
| | Intention | 1 | 2017 | 183 | 0.110 |
Why?
| | Health Knowledge, Attitudes, Practice | 3 | 2023 | 1414 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2021 | 1560 | 0.110 |
Why?
| | Cluster Analysis | 1 | 2016 | 521 | 0.110 |
Why?
| | Viral Load | 1 | 2017 | 526 | 0.110 |
Why?
| | Sebaceous Glands | 1 | 2014 | 5 | 0.110 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2015 | 37 | 0.110 |
Why?
| | Kava | 1 | 2014 | 3 | 0.110 |
Why?
| | Cause of Death | 1 | 2017 | 471 | 0.110 |
Why?
| | Multivariate Analysis | 3 | 2016 | 1539 | 0.110 |
Why?
| | Drug Eruptions | 1 | 2014 | 28 | 0.110 |
Why?
| | Patient Education as Topic | 1 | 2020 | 780 | 0.110 |
Why?
| | Fetal Blood | 1 | 2017 | 342 | 0.110 |
Why?
| | Plant Preparations | 1 | 2014 | 37 | 0.110 |
Why?
| | Surgeons | 1 | 2019 | 339 | 0.110 |
Why?
| | Motivation | 1 | 2019 | 610 | 0.110 |
Why?
| | Phytotherapy | 1 | 2014 | 74 | 0.100 |
Why?
| | Body Mass Index | 2 | 2021 | 2438 | 0.100 |
Why?
| | Transcription, Genetic | 1 | 2020 | 1496 | 0.100 |
Why?
| | Sex Characteristics | 1 | 2019 | 790 | 0.100 |
Why?
| | Exanthema | 1 | 2014 | 84 | 0.100 |
Why?
| | Transcriptome | 1 | 2020 | 1045 | 0.100 |
Why?
| | Health Personnel | 2 | 2017 | 748 | 0.100 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2014 | 118 | 0.100 |
Why?
| | Veterans | 1 | 2026 | 1603 | 0.100 |
Why?
| | Referral and Consultation | 1 | 2020 | 851 | 0.100 |
Why?
| | Hand | 2 | 2026 | 161 | 0.100 |
Why?
| | Stomach Neoplasms | 1 | 2015 | 126 | 0.100 |
Why?
| | Clinical Coding | 1 | 2013 | 25 | 0.100 |
Why?
| | Animals | 7 | 2021 | 38058 | 0.100 |
Why?
| | Systematized Nomenclature of Medicine | 1 | 2013 | 13 | 0.100 |
Why?
| | Gastrectomy | 1 | 2015 | 161 | 0.100 |
Why?
| | Lip Neoplasms | 1 | 2012 | 2 | 0.100 |
Why?
| | Hydrochlorothiazide | 1 | 2012 | 7 | 0.090 |
Why?
| | Signal Transduction | 2 | 2019 | 5226 | 0.090 |
Why?
| | Nifedipine | 1 | 2012 | 27 | 0.090 |
Why?
| | Calcium, Dietary | 1 | 2012 | 53 | 0.090 |
Why?
| | Mutation | 3 | 2019 | 4089 | 0.090 |
Why?
| | Sunscreening Agents | 1 | 2012 | 25 | 0.090 |
Why?
| | Arthritis, Juvenile | 1 | 2013 | 56 | 0.090 |
Why?
| | Skin Transplantation | 2 | 2004 | 85 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2019 | 917 | 0.090 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2012 | 529 | 0.090 |
Why?
| | Methotrexate | 1 | 2013 | 240 | 0.090 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1313 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1455 | 0.090 |
Why?
| | Computer-Assisted Instruction | 1 | 2012 | 71 | 0.090 |
Why?
| | Genetic Testing | 2 | 2019 | 478 | 0.090 |
Why?
| | Mortality | 1 | 2015 | 375 | 0.090 |
Why?
| | Professional Competence | 1 | 2012 | 98 | 0.090 |
Why?
| | Graft Rejection | 1 | 2015 | 540 | 0.090 |
Why?
| | Fees and Charges | 1 | 2011 | 11 | 0.090 |
Why?
| | Lung Transplantation | 1 | 2015 | 338 | 0.090 |
Why?
| | Private Practice | 1 | 2011 | 19 | 0.090 |
Why?
| | Marital Status | 1 | 2011 | 46 | 0.090 |
Why?
| | Diagnosis, Differential | 3 | 2007 | 1489 | 0.090 |
Why?
| | Electrosurgery | 1 | 2012 | 42 | 0.090 |
Why?
| | Food | 1 | 2012 | 149 | 0.090 |
Why?
| | Hedgehog Proteins | 1 | 2012 | 197 | 0.090 |
Why?
| | Nutrition Surveys | 1 | 2012 | 282 | 0.080 |
Why?
| | Homeodomain Proteins | 1 | 2015 | 523 | 0.080 |
Why?
| | Basal Cell Nevus Syndrome | 1 | 2010 | 7 | 0.080 |
Why?
| | Postoperative Hemorrhage | 1 | 2011 | 104 | 0.080 |
Why?
| | Program Development | 1 | 2012 | 370 | 0.080 |
Why?
| | Physicians | 1 | 2019 | 939 | 0.080 |
Why?
| | Immune Tolerance | 1 | 2012 | 379 | 0.080 |
Why?
| | Neoplasms, Basal Cell | 1 | 2009 | 4 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2023 | 2452 | 0.080 |
Why?
| | Curriculum | 1 | 2017 | 1059 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2018 | 1098 | 0.080 |
Why?
| | Family Relations | 1 | 2010 | 88 | 0.080 |
Why?
| | Aspirin | 1 | 2013 | 399 | 0.080 |
Why?
| | DNA Damage | 1 | 2012 | 430 | 0.080 |
Why?
| | Education, Medical | 1 | 2012 | 274 | 0.070 |
Why?
| | Faculty, Medical | 1 | 2012 | 302 | 0.070 |
Why?
| | Life Style | 1 | 2012 | 479 | 0.070 |
Why?
| | Genetic Counseling | 1 | 2009 | 81 | 0.070 |
Why?
| | Eggs | 1 | 2009 | 25 | 0.070 |
Why?
| | Northwestern United States | 1 | 2008 | 58 | 0.070 |
Why?
| | Fishes | 1 | 2009 | 108 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2022 | 2637 | 0.070 |
Why?
| | Behavior Therapy | 1 | 2011 | 299 | 0.070 |
Why?
| | Cross-Sectional Studies | 2 | 2018 | 5868 | 0.070 |
Why?
| | Milk | 1 | 2009 | 119 | 0.070 |
Why?
| | Phylogeny | 2 | 2015 | 1016 | 0.070 |
Why?
| | Cervix Uteri | 1 | 2007 | 50 | 0.070 |
Why?
| | Health Behavior | 2 | 2017 | 785 | 0.070 |
Why?
| | Adenocarcinoma | 1 | 2015 | 928 | 0.070 |
Why?
| | Energy Metabolism | 1 | 2013 | 935 | 0.070 |
Why?
| | Time Factors | 3 | 2017 | 7173 | 0.070 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 974 | 0.070 |
Why?
| | Disclosure | 1 | 2007 | 85 | 0.060 |
Why?
| | Head-Down Tilt | 1 | 2007 | 6 | 0.060 |
Why?
| | Torsion Abnormality | 1 | 2007 | 20 | 0.060 |
Why?
| | Psychological Theory | 1 | 2007 | 93 | 0.060 |
Why?
| | Risk Reduction Behavior | 1 | 2009 | 226 | 0.060 |
Why?
| | Arthritis, Rheumatoid | 1 | 2015 | 1169 | 0.060 |
Why?
| | Eccrine Glands | 1 | 2006 | 2 | 0.060 |
Why?
| | Sweat Gland Diseases | 1 | 2006 | 2 | 0.060 |
Why?
| | Eosinophil-Derived Neurotoxin | 1 | 2006 | 3 | 0.060 |
Why?
| | Mupirocin | 1 | 2006 | 7 | 0.060 |
Why?
| | Eosinophil Major Basic Protein | 1 | 2006 | 7 | 0.060 |
Why?
| | Arteriovenous Malformations | 1 | 2006 | 29 | 0.060 |
Why?
| | Hamartoma | 1 | 2006 | 29 | 0.060 |
Why?
| | Bandages | 1 | 2006 | 42 | 0.060 |
Why?
| | Acetaminophen | 1 | 2008 | 264 | 0.060 |
Why?
| | Postoperative Complications | 2 | 2015 | 2919 | 0.060 |
Why?
| | Clinical Competence | 1 | 2013 | 1244 | 0.060 |
Why?
| | Sodium Chloride | 1 | 2006 | 141 | 0.060 |
Why?
| | Environmental Exposure | 1 | 2009 | 588 | 0.060 |
Why?
| | Primary Health Care | 2 | 2017 | 1733 | 0.050 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 74 | 0.050 |
Why?
| | Necrosis | 1 | 2005 | 244 | 0.050 |
Why?
| | Anti-Bacterial Agents | 2 | 2023 | 1907 | 0.050 |
Why?
| | Cyclooxygenase 2 | 1 | 2004 | 165 | 0.050 |
Why?
| | Patient-Centered Care | 1 | 2009 | 544 | 0.050 |
Why?
| | Communication | 1 | 2010 | 965 | 0.050 |
Why?
| | Isoenzymes | 1 | 2004 | 299 | 0.050 |
Why?
| | Vaccination | 2 | 2023 | 1423 | 0.050 |
Why?
| | New York | 1 | 2023 | 125 | 0.050 |
Why?
| | Societies, Medical | 2 | 2018 | 887 | 0.050 |
Why?
| | Mucous Membrane | 1 | 2023 | 127 | 0.050 |
Why?
| | Socioeconomic Factors | 2 | 2021 | 1326 | 0.050 |
Why?
| | Public Health | 1 | 2007 | 566 | 0.050 |
Why?
| | Surgical Mesh | 1 | 2002 | 50 | 0.040 |
Why?
| | Diclofenac | 1 | 2021 | 14 | 0.040 |
Why?
| | Infant, Premature | 1 | 2006 | 611 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2004 | 478 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1266 | 0.040 |
Why?
| | Ligands | 1 | 2022 | 673 | 0.040 |
Why?
| | Delphi Technique | 1 | 2021 | 329 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2022 | 241 | 0.040 |
Why?
| | Hospitalization | 2 | 2023 | 2433 | 0.040 |
Why?
| | Hair Follicle | 1 | 1999 | 48 | 0.040 |
Why?
| | Ipilimumab | 1 | 2019 | 39 | 0.040 |
Why?
| | Cell Size | 1 | 1999 | 92 | 0.040 |
Why?
| | Antibody Specificity | 1 | 1999 | 181 | 0.040 |
Why?
| | Immunoenzyme Techniques | 1 | 1999 | 200 | 0.040 |
Why?
| | Oncogenes | 1 | 2019 | 119 | 0.040 |
Why?
| | Lung Diseases, Obstructive | 1 | 1998 | 43 | 0.030 |
Why?
| | Keratoacanthoma | 1 | 2017 | 2 | 0.030 |
Why?
| | Photosensitivity Disorders | 1 | 2017 | 8 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2004 | 1166 | 0.030 |
Why?
| | Urban Health | 1 | 1998 | 96 | 0.030 |
Why?
| | Rural Health | 1 | 1998 | 87 | 0.030 |
Why?
| | PUVA Therapy | 1 | 1997 | 6 | 0.030 |
Why?
| | Retinoids | 1 | 2017 | 33 | 0.030 |
Why?
| | Capecitabine | 1 | 2017 | 57 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2019 | 229 | 0.030 |
Why?
| | Risk Adjustment | 1 | 2018 | 85 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 1999 | 919 | 0.030 |
Why?
| | Vitamin B Complex | 1 | 2017 | 40 | 0.030 |
Why?
| | Reimbursement Mechanisms | 1 | 2018 | 80 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2018 | 129 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2018 | 248 | 0.030 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2017 | 105 | 0.030 |
Why?
| | Niacinamide | 1 | 2017 | 86 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2017 | 222 | 0.030 |
Why?
| | Splenectomy | 1 | 1997 | 65 | 0.030 |
Why?
| | Pregnancy Trimester, Second | 1 | 2017 | 82 | 0.030 |
Why?
| | Primary Prevention | 1 | 2018 | 220 | 0.030 |
Why?
| | Rheumatologists | 1 | 2016 | 15 | 0.030 |
Why?
| | Decision Making | 1 | 2024 | 975 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 339 | 0.030 |
Why?
| | Computers | 1 | 2016 | 67 | 0.030 |
Why?
| | Pregnancy Trimester, First | 1 | 2017 | 136 | 0.030 |
Why?
| | Drugs, Generic | 1 | 2016 | 27 | 0.030 |
Why?
| | Sampling Studies | 1 | 2016 | 99 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2016 | 183 | 0.030 |
Why?
| | Visual Pathways | 1 | 1996 | 61 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 1998 | 547 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2001 | 1053 | 0.030 |
Why?
| | Medical Records Systems, Computerized | 1 | 2016 | 95 | 0.030 |
Why?
| | Developing Countries | 1 | 1998 | 318 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 341 | 0.030 |
Why?
| | Pattern Recognition, Visual | 1 | 1996 | 105 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 688 | 0.030 |
Why?
| | Research | 1 | 2018 | 431 | 0.030 |
Why?
| | Photic Stimulation | 1 | 1996 | 264 | 0.030 |
Why?
| | Pharmacoepidemiology | 1 | 2015 | 22 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 688 | 0.030 |
Why?
| | Gene Expression | 1 | 2020 | 1490 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1694 | 0.030 |
Why?
| | Erythema | 1 | 2014 | 28 | 0.030 |
Why?
| | Health Expenditures | 1 | 2016 | 194 | 0.030 |
Why?
| | Antifungal Agents | 1 | 2015 | 149 | 0.030 |
Why?
| | Disease Management | 1 | 2018 | 645 | 0.030 |
Why?
| | Prenatal Care | 1 | 2017 | 307 | 0.030 |
Why?
| | Mice | 3 | 2021 | 18339 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 1953 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2015 | 172 | 0.030 |
Why?
| | Papillomavirus Vaccines | 1 | 2017 | 297 | 0.030 |
Why?
| | Phototherapy | 1 | 2013 | 48 | 0.030 |
Why?
| | Infliximab | 1 | 2013 | 108 | 0.020 |
Why?
| | Air Pollutants | 1 | 1998 | 438 | 0.020 |
Why?
| | Computer User Training | 1 | 2012 | 5 | 0.020 |
Why?
| | Graft Survival | 1 | 2015 | 526 | 0.020 |
Why?
| | Medicaid | 1 | 2016 | 461 | 0.020 |
Why?
| | Codon | 1 | 2012 | 94 | 0.020 |
Why?
| | Washington | 1 | 2012 | 147 | 0.020 |
Why?
| | Ibuprofen | 1 | 2012 | 84 | 0.020 |
Why?
| | Postmenopause | 1 | 2013 | 391 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2015 | 1095 | 0.020 |
Why?
| | Medicare | 1 | 2016 | 886 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3409 | 0.020 |
Why?
| | Regression Analysis | 1 | 2012 | 1003 | 0.020 |
Why?
| | Histoplasmosis | 1 | 1970 | 15 | 0.020 |
Why?
| | Coccidioidomycosis | 1 | 1970 | 7 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2011 | 249 | 0.020 |
Why?
| | Skin Tests | 1 | 1970 | 94 | 0.020 |
Why?
| | Michigan | 1 | 2009 | 136 | 0.020 |
Why?
| | Family Characteristics | 1 | 2010 | 197 | 0.020 |
Why?
| | Lipids | 1 | 2013 | 710 | 0.020 |
Why?
| | Papanicolaou Test | 1 | 2007 | 35 | 0.020 |
Why?
| | Health Surveys | 1 | 1970 | 518 | 0.020 |
Why?
| | Vaginal Smears | 1 | 2007 | 55 | 0.020 |
Why?
| | Psychology | 1 | 2007 | 88 | 0.020 |
Why?
| | Blood Pressure | 1 | 2013 | 1769 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2007 | 166 | 0.010 |
Why?
| | Iran | 2 | 1998 | 44 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1720 | 0.010 |
Why?
| | Pregnancy | 1 | 2017 | 7190 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 1996 | 3863 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2012 | 845 | 0.010 |
Why?
| | Blood Glucose | 1 | 2013 | 2327 | 0.010 |
Why?
| | Varicose Ulcer | 1 | 2002 | 5 | 0.010 |
Why?
| | Diabetic Foot | 1 | 2002 | 25 | 0.010 |
Why?
| | Wound Healing | 1 | 2002 | 351 | 0.010 |
Why?
| | Sulfur Oxides | 1 | 1998 | 1 | 0.010 |
Why?
| | Nitrogen Oxides | 1 | 1998 | 54 | 0.010 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 1997 | 26 | 0.010 |
Why?
| | Spirometry | 1 | 1998 | 231 | 0.010 |
Why?
| | Visual Cortex | 1 | 1996 | 84 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1997 | 1054 | 0.010 |
Why?
| | Brain Mapping | 1 | 1996 | 536 | 0.010 |
Why?
| | Histoplasmin | 1 | 1970 | 1 | 0.000 |
Why?
| | Mass Chest X-Ray | 1 | 1970 | 4 | 0.000 |
Why?
| | Histoplasma | 1 | 1970 | 9 | 0.000 |
Why?
| | Coccidioides | 1 | 1970 | 6 | 0.000 |
Why?
| | Blood Cell Count | 1 | 1970 | 54 | 0.000 |
Why?
| | Tuberculin Test | 1 | 1970 | 36 | 0.000 |
Why?
| | Occupations | 1 | 1970 | 51 | 0.000 |
Why?
| | Climate | 1 | 1970 | 89 | 0.000 |
Why?
| | Antigens | 1 | 1970 | 347 | 0.000 |
Why?
| | Sputum | 1 | 1970 | 308 | 0.000 |
Why?
| | Soil Microbiology | 1 | 1970 | 218 | 0.000 |
Why?
| | Rural Population | 1 | 1970 | 650 | 0.000 |
Why?
|
|
Asgari's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|